JP2008528519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528519A5 JP2008528519A5 JP2007552413A JP2007552413A JP2008528519A5 JP 2008528519 A5 JP2008528519 A5 JP 2008528519A5 JP 2007552413 A JP2007552413 A JP 2007552413A JP 2007552413 A JP2007552413 A JP 2007552413A JP 2008528519 A5 JP2008528519 A5 JP 2008528519A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- methyl
- thiophen
- phenyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 125000005843 halogen group Chemical group 0.000 claims 21
- -1 3,5-difluoro-pyridin-4-ylcarbamoyl Chemical group 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000004438 haloalkoxy group Chemical group 0.000 claims 16
- 125000001188 haloalkyl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 9
- 125000000547 substituted alkyl group Chemical group 0.000 claims 9
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 9
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 5
- 102000004310 Ion Channels Human genes 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 230000005931 immune cell recruitment Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- SCRHWKOZSWUPKR-UHFFFAOYSA-N 3-methyl-n-[5-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(S1)=CC=C1NC(=O)C1=CC=NC=C1C SCRHWKOZSWUPKR-UHFFFAOYSA-N 0.000 claims 2
- SZUVFRSOGIBPNO-UHFFFAOYSA-N 5-(5-carbamoyl-2-methylphenyl)-n-(2,6-difluorophenyl)thiophene-2-carboxamide Chemical compound CC1=CC=C(C(N)=O)C=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 SZUVFRSOGIBPNO-UHFFFAOYSA-N 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 claims 2
- ACGGWEQWSHHHPS-UHFFFAOYSA-N methyl 3-chloro-4-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]benzoate Chemical compound ClC1=CC(C(=O)OC)=CC=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 ACGGWEQWSHHHPS-UHFFFAOYSA-N 0.000 claims 2
- BAEBBDIFQSEKMY-UHFFFAOYSA-N methyl 4-methyl-3-[5-[(3-methylpyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2)C)=C1 BAEBBDIFQSEKMY-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- DFFBRMLHLXNTBV-UHFFFAOYSA-N propyl 4-chloro-3-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]benzoate Chemical compound CCCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CC=CC=2F)F)=C1 DFFBRMLHLXNTBV-UHFFFAOYSA-N 0.000 claims 2
- RMTLHQQETULZDK-UHFFFAOYSA-N 2,6-difluoro-n-[5-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]thiophen-2-yl]benzamide Chemical compound CC1=CC=C(C=2OC=CN=2)C=C1C(S1)=CC=C1NC(=O)C1=C(F)C=CC=C1F RMTLHQQETULZDK-UHFFFAOYSA-N 0.000 claims 1
- UELRFSJDXDLMOI-UHFFFAOYSA-N 2,6-difluoro-n-[5-[3-(trifluoromethyl)phenyl]thiophen-2-yl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)S1 UELRFSJDXDLMOI-UHFFFAOYSA-N 0.000 claims 1
- MDHWZJUMDNYPNM-UHFFFAOYSA-N 2-methoxyethyl 3-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]-4-methylbenzoate Chemical compound COCCOC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CC=CC=2F)F)=C1 MDHWZJUMDNYPNM-UHFFFAOYSA-N 0.000 claims 1
- HPOVNSVWDXOZEN-UHFFFAOYSA-N 2-methoxyethyl 3-[5-[(3,5-difluoropyridin-4-yl)carbamoyl]thiophen-2-yl]-4-methylbenzoate Chemical compound COCCOC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2F)F)=C1 HPOVNSVWDXOZEN-UHFFFAOYSA-N 0.000 claims 1
- XJKYXJZNGKCQAZ-UHFFFAOYSA-N 2-methoxyethyl 3-chloro-4-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]benzoate Chemical compound ClC1=CC(C(=O)OCCOC)=CC=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 XJKYXJZNGKCQAZ-UHFFFAOYSA-N 0.000 claims 1
- OIAGDNSHPPQUJO-UHFFFAOYSA-N 2-methoxyethyl 4-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OCCOC)=CC=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 OIAGDNSHPPQUJO-UHFFFAOYSA-N 0.000 claims 1
- ZAHFPKWOQJHYTI-UHFFFAOYSA-N 2-methoxyethyl 4-chloro-3-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]benzoate Chemical compound COCCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CC=CC=2F)F)=C1 ZAHFPKWOQJHYTI-UHFFFAOYSA-N 0.000 claims 1
- TZGJAIZYYKTUAY-UHFFFAOYSA-N 2-methoxyethyl 4-chloro-3-[5-[(3,5-difluoropyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound COCCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2F)F)=C1 TZGJAIZYYKTUAY-UHFFFAOYSA-N 0.000 claims 1
- OLTLNUWCRQNFDV-UHFFFAOYSA-N 2-methoxyethyl 4-chloro-3-[5-[(3-methylpyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound COCCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2)C)=C1 OLTLNUWCRQNFDV-UHFFFAOYSA-N 0.000 claims 1
- XCRYJKQSYMEMPM-UHFFFAOYSA-N 2-methoxyethyl 4-methyl-3-[5-[(3-methylpyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound COCCOC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2)C)=C1 XCRYJKQSYMEMPM-UHFFFAOYSA-N 0.000 claims 1
- YKVCQIOABFYYHR-UHFFFAOYSA-N 3,5-difluoro-n-[5-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(S1)=CC=C1NC(=O)C1=C(F)C=NC=C1F YKVCQIOABFYYHR-UHFFFAOYSA-N 0.000 claims 1
- HYJANQFYIOQISJ-UHFFFAOYSA-N 3,5-difluoro-n-[5-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(S1)=CC=C1NC(=O)C1=C(F)C=NC=C1F HYJANQFYIOQISJ-UHFFFAOYSA-N 0.000 claims 1
- FWPVEECGGXZVAM-UHFFFAOYSA-N 3,5-difluoro-n-[5-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=CN=2)C=C1C(S1)=CC=C1NC(=O)C1=C(F)C=NC=C1F FWPVEECGGXZVAM-UHFFFAOYSA-N 0.000 claims 1
- JNNKPLGLXGSHAC-UHFFFAOYSA-N 3,5-difluoro-n-[5-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=CN=2)C=C1C(S1)=CC=C1NC(=O)C1=C(F)C=NC=C1F JNNKPLGLXGSHAC-UHFFFAOYSA-N 0.000 claims 1
- NTSOTTUZKUTNQU-UHFFFAOYSA-N 3-fluoro-n-[5-[2-methyl-5-(1,2-oxazol-5-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2ON=CC=2)C=C1C(S1)=CC=C1NC(=O)C1=CC=NC=C1F NTSOTTUZKUTNQU-UHFFFAOYSA-N 0.000 claims 1
- PTEJNWGOBSKDCI-UHFFFAOYSA-N 3-fluoro-n-[5-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(S1)=CC=C1NC(=O)C1=CC=NC=C1F PTEJNWGOBSKDCI-UHFFFAOYSA-N 0.000 claims 1
- NQVOKZGDLMVMOE-UHFFFAOYSA-N 3-fluoro-n-[5-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(S1)=CC=C1NC(=O)C1=CC=NC=C1F NQVOKZGDLMVMOE-UHFFFAOYSA-N 0.000 claims 1
- SCHJWFVIHDUIDE-UHFFFAOYSA-N 3-fluoro-n-[5-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=CN=2)C=C1C(S1)=CC=C1NC(=O)C1=CC=NC=C1F SCHJWFVIHDUIDE-UHFFFAOYSA-N 0.000 claims 1
- HMTVKTCKCSRNSG-UHFFFAOYSA-N 3-methyl-n-[5-[2-methyl-5-(1,2-oxazol-5-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2ON=CC=2)C=C1C(S1)=CC=C1NC(=O)C1=CC=NC=C1C HMTVKTCKCSRNSG-UHFFFAOYSA-N 0.000 claims 1
- JSLGZZWANSGFFA-UHFFFAOYSA-N 3-methyl-n-[5-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]thiophen-2-yl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=CN=2)C=C1C(S1)=CC=C1NC(=O)C1=CC=NC=C1C JSLGZZWANSGFFA-UHFFFAOYSA-N 0.000 claims 1
- RLCIPEANWMGUII-UHFFFAOYSA-N 5-(5-bromo-2-methoxypyridin-3-yl)-n-(2,6-difluorophenyl)thiophene-2-carboxamide Chemical compound COC1=NC=C(Br)C=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 RLCIPEANWMGUII-UHFFFAOYSA-N 0.000 claims 1
- CNPMNPDDRZQEHW-UHFFFAOYSA-N 5-(5-bromo-2-methoxypyridin-3-yl)-n-(3,5-difluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound COC1=NC=C(Br)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2F)F)S1 CNPMNPDDRZQEHW-UHFFFAOYSA-N 0.000 claims 1
- GRKXGTHICDNIBR-UHFFFAOYSA-N 5-(5-bromo-2-methoxypyridin-3-yl)-n-(3-fluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound COC1=NC=C(Br)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)F)S1 GRKXGTHICDNIBR-UHFFFAOYSA-N 0.000 claims 1
- ICGNIEKBYLVFFF-UHFFFAOYSA-N 5-(5-bromo-2-methoxypyridin-3-yl)-n-(3-methylpyridin-4-yl)thiophene-2-carboxamide Chemical compound COC1=NC=C(Br)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)C)S1 ICGNIEKBYLVFFF-UHFFFAOYSA-N 0.000 claims 1
- HDQZPHBCASKWMW-UHFFFAOYSA-N 5-(5-carbamoyl-2-methylphenyl)-n-(3,5-difluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound CC1=CC=C(C(N)=O)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2F)F)S1 HDQZPHBCASKWMW-UHFFFAOYSA-N 0.000 claims 1
- YLNLHLZSKRNCJH-UHFFFAOYSA-N 5-(5-carbamoyl-2-methylphenyl)-n-(3-fluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound CC1=CC=C(C(N)=O)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)F)S1 YLNLHLZSKRNCJH-UHFFFAOYSA-N 0.000 claims 1
- GNYSHBLOQSPQCW-UHFFFAOYSA-N 5-(5-carbamoyl-2-methylphenyl)-n-(3-methylpyridin-4-yl)thiophene-2-carboxamide Chemical compound CC1=CC=C(C(N)=O)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)C)S1 GNYSHBLOQSPQCW-UHFFFAOYSA-N 0.000 claims 1
- XXRNWZQWAGYWQG-UHFFFAOYSA-N 5-(5-chloro-2-methoxypyridin-3-yl)-n-(2,6-difluorophenyl)thiophene-2-carboxamide Chemical compound COC1=NC=C(Cl)C=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 XXRNWZQWAGYWQG-UHFFFAOYSA-N 0.000 claims 1
- JRUGWMFEMJFCEK-UHFFFAOYSA-N 5-(5-chloro-2-methoxypyridin-3-yl)-n-(3,5-difluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound COC1=NC=C(Cl)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2F)F)S1 JRUGWMFEMJFCEK-UHFFFAOYSA-N 0.000 claims 1
- ZDLMXOGDJFFDLU-UHFFFAOYSA-N 5-(5-chloro-2-methoxypyridin-3-yl)-n-(3-fluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound COC1=NC=C(Cl)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)F)S1 ZDLMXOGDJFFDLU-UHFFFAOYSA-N 0.000 claims 1
- SBKWIGZHNKHPNS-UHFFFAOYSA-N 5-(5-chloro-2-methoxypyridin-3-yl)-n-(3-methylpyridin-4-yl)thiophene-2-carboxamide Chemical compound COC1=NC=C(Cl)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)C)S1 SBKWIGZHNKHPNS-UHFFFAOYSA-N 0.000 claims 1
- PCKSUQPUEASMEU-UHFFFAOYSA-N 5-(5-cyano-2-methylphenyl)-n-(3,5-difluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound CC1=CC=C(C#N)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2F)F)S1 PCKSUQPUEASMEU-UHFFFAOYSA-N 0.000 claims 1
- AYBBZFKTQHXGRA-UHFFFAOYSA-N 5-(5-cyano-2-methylphenyl)-n-(3-fluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound CC1=CC=C(C#N)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)F)S1 AYBBZFKTQHXGRA-UHFFFAOYSA-N 0.000 claims 1
- RKWCKMRWRMBMHD-UHFFFAOYSA-N 5-(5-cyano-2-methylphenyl)-n-(3-methylpyridin-4-yl)thiophene-2-carboxamide Chemical compound CC1=CC=C(C#N)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)C)S1 RKWCKMRWRMBMHD-UHFFFAOYSA-N 0.000 claims 1
- ZYPDOLOIVUQBHA-UHFFFAOYSA-N 5-[2-chloro-5-(trifluoromethyl)phenyl]-n-(2,6-difluorophenyl)thiophene-2-carboxamide Chemical compound FC1=CC=CC(F)=C1NC(=O)C1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)S1 ZYPDOLOIVUQBHA-UHFFFAOYSA-N 0.000 claims 1
- GZQRIUNYAKGDOX-UHFFFAOYSA-N 5-[2-chloro-5-(trifluoromethyl)phenyl]-n-(3-methylpyridin-4-yl)thiophene-2-carboxamide Chemical compound CC1=CN=CC=C1NC(=O)C1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)S1 GZQRIUNYAKGDOX-UHFFFAOYSA-N 0.000 claims 1
- XBWNZVFKRWKSBP-UHFFFAOYSA-N 5-[2-ethyl-5-(trifluoromethyl)phenyl]-n-(3-fluoropyridin-4-yl)thiophene-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)F)S1 XBWNZVFKRWKSBP-UHFFFAOYSA-N 0.000 claims 1
- JYQDNGRDKIYQQC-UHFFFAOYSA-N 5-[2-ethyl-5-(trifluoromethyl)phenyl]-n-(3-methylpyridin-4-yl)thiophene-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)C)S1 JYQDNGRDKIYQQC-UHFFFAOYSA-N 0.000 claims 1
- OKDINCQPRYXHSL-UHFFFAOYSA-N 5-[5-(furan-2-yl)-2-methoxypyridin-3-yl]-n-(3-methylpyridin-4-yl)thiophene-2-carboxamide Chemical compound COC1=NC=C(C=2OC=CC=2)C=C1C(S1)=CC=C1C(=O)NC1=CC=NC=C1C OKDINCQPRYXHSL-UHFFFAOYSA-N 0.000 claims 1
- FDQOESXHIHKIGV-UHFFFAOYSA-N 5-[5-(furan-3-yl)-2-methoxypyridin-3-yl]-n-(3-methylpyridin-4-yl)thiophene-2-carboxamide Chemical compound COC1=NC=C(C2=COC=C2)C=C1C(S1)=CC=C1C(=O)NC1=CC=NC=C1C FDQOESXHIHKIGV-UHFFFAOYSA-N 0.000 claims 1
- VSBQYZXBNQEHLV-UHFFFAOYSA-N ClC1(C(C=CC=C1)C1=CC=C(S1)NC(C1=C(C=NC=C1)C)=O)C=1OC=NN1 Chemical compound ClC1(C(C=CC=C1)C1=CC=C(S1)NC(C1=C(C=NC=C1)C)=O)C=1OC=NN1 VSBQYZXBNQEHLV-UHFFFAOYSA-N 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VTTVLIMPVVYGMM-UHFFFAOYSA-N ethyl 3-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]-4-methylbenzoate Chemical compound CCOC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CC=CC=2F)F)=C1 VTTVLIMPVVYGMM-UHFFFAOYSA-N 0.000 claims 1
- VADOEKDINFXHTJ-UHFFFAOYSA-N ethyl 4-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OCC)=CC=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 VADOEKDINFXHTJ-UHFFFAOYSA-N 0.000 claims 1
- IYNWLRQDGPVPGP-UHFFFAOYSA-N ethyl 4-chloro-3-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CC=CC=2F)F)=C1 IYNWLRQDGPVPGP-UHFFFAOYSA-N 0.000 claims 1
- ZSNNOVGLLCRCKD-UHFFFAOYSA-N ethyl 4-chloro-3-[5-[(3,5-difluoropyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2F)F)=C1 ZSNNOVGLLCRCKD-UHFFFAOYSA-N 0.000 claims 1
- DEJAQEQQWYEFPN-UHFFFAOYSA-N ethyl 4-chloro-3-[5-[(3-methylpyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2)C)=C1 DEJAQEQQWYEFPN-UHFFFAOYSA-N 0.000 claims 1
- HXFXAPUMGFSCQK-UHFFFAOYSA-N ethyl 4-methyl-3-[5-[(3-methylpyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2)C)=C1 HXFXAPUMGFSCQK-UHFFFAOYSA-N 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- GQZXIYHNNGWDGX-UHFFFAOYSA-N methyl 3-[5-[(2,6-difluorobenzoyl)amino]thiophen-2-yl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2SC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 GQZXIYHNNGWDGX-UHFFFAOYSA-N 0.000 claims 1
- CYEJEUFHAKJVMF-UHFFFAOYSA-N methyl 3-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CC=CC=2F)F)=C1 CYEJEUFHAKJVMF-UHFFFAOYSA-N 0.000 claims 1
- ORUKKECDBDGFIM-UHFFFAOYSA-N methyl 3-[5-[(3,5-difluoropyridin-4-yl)carbamoyl]thiophen-2-yl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2F)F)=C1 ORUKKECDBDGFIM-UHFFFAOYSA-N 0.000 claims 1
- REQQGAUMSBGJPI-UHFFFAOYSA-N methyl 4-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 REQQGAUMSBGJPI-UHFFFAOYSA-N 0.000 claims 1
- QFLYFAOOVUOQHD-UHFFFAOYSA-N methyl 4-chloro-3-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]benzoate Chemical compound COC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CC=CC=2F)F)=C1 QFLYFAOOVUOQHD-UHFFFAOYSA-N 0.000 claims 1
- CQMXPXDTNXHFFE-UHFFFAOYSA-N methyl 4-chloro-3-[5-[(3,5-difluoropyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound COC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2F)F)=C1 CQMXPXDTNXHFFE-UHFFFAOYSA-N 0.000 claims 1
- ORYPORMNFULBEL-UHFFFAOYSA-N methyl 4-chloro-3-[5-[(3-methylpyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound COC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2)C)=C1 ORYPORMNFULBEL-UHFFFAOYSA-N 0.000 claims 1
- SLOXFLKTCNMQSU-UHFFFAOYSA-N n-(2,6-difluorophenyl)-5-[2-ethyl-5-(trifluoromethyl)phenyl]thiophene-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 SLOXFLKTCNMQSU-UHFFFAOYSA-N 0.000 claims 1
- LBHGTPYMPASOAI-UHFFFAOYSA-N n-(2,6-difluorophenyl)-5-[2-methyl-5-(trifluoromethyl)phenyl]thiophene-2-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 LBHGTPYMPASOAI-UHFFFAOYSA-N 0.000 claims 1
- NDSNELQVLUTLRF-UHFFFAOYSA-N n-(2,6-difluorophenyl)-5-[5-(furan-2-yl)-2-methoxypyridin-3-yl]thiophene-2-carboxamide Chemical compound COC1=NC=C(C=2OC=CC=2)C=C1C(S1)=CC=C1C(=O)NC1=C(F)C=CC=C1F NDSNELQVLUTLRF-UHFFFAOYSA-N 0.000 claims 1
- IUXQNLFKLUJFOW-UHFFFAOYSA-N n-(2,6-difluorophenyl)-5-[5-(furan-3-yl)-2-methoxypyridin-3-yl]thiophene-2-carboxamide Chemical compound COC1=NC=C(C2=COC=C2)C=C1C(S1)=CC=C1C(=O)NC1=C(F)C=CC=C1F IUXQNLFKLUJFOW-UHFFFAOYSA-N 0.000 claims 1
- LZQCXRBGAIZPSU-UHFFFAOYSA-N n-(3,5-difluoropyridin-4-yl)-5-[2-ethyl-5-(trifluoromethyl)phenyl]thiophene-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2F)F)S1 LZQCXRBGAIZPSU-UHFFFAOYSA-N 0.000 claims 1
- IAGOEFHSWWZIBS-UHFFFAOYSA-N n-(3,5-difluoropyridin-4-yl)-5-[2-methyl-5-(trifluoromethyl)phenyl]thiophene-2-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2F)F)S1 IAGOEFHSWWZIBS-UHFFFAOYSA-N 0.000 claims 1
- DASXDCLBRXVGGF-UHFFFAOYSA-N n-(3,5-difluoropyridin-4-yl)-5-[5-(furan-2-yl)-2-methoxypyridin-3-yl]thiophene-2-carboxamide Chemical compound COC1=NC=C(C=2OC=CC=2)C=C1C(S1)=CC=C1C(=O)NC1=C(F)C=NC=C1F DASXDCLBRXVGGF-UHFFFAOYSA-N 0.000 claims 1
- AGYJVBRJNSFQOI-UHFFFAOYSA-N n-(3,5-difluoropyridin-4-yl)-5-[5-(furan-3-yl)-2-methoxypyridin-3-yl]thiophene-2-carboxamide Chemical compound COC1=NC=C(C2=COC=C2)C=C1C(S1)=CC=C1C(=O)NC1=C(F)C=NC=C1F AGYJVBRJNSFQOI-UHFFFAOYSA-N 0.000 claims 1
- RUHNBFUTTOPAGB-UHFFFAOYSA-N n-(3-fluoropyridin-4-yl)-5-[2-methyl-5-(trifluoromethyl)phenyl]thiophene-2-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=CC=C(C(=O)NC=2C(=CN=CC=2)F)S1 RUHNBFUTTOPAGB-UHFFFAOYSA-N 0.000 claims 1
- DUKQNODGMHRAAR-UHFFFAOYSA-N n-(3-fluoropyridin-4-yl)-5-[5-(furan-2-yl)-2-methoxypyridin-3-yl]thiophene-2-carboxamide Chemical compound COC1=NC=C(C=2OC=CC=2)C=C1C(S1)=CC=C1C(=O)NC1=CC=NC=C1F DUKQNODGMHRAAR-UHFFFAOYSA-N 0.000 claims 1
- DTLUVEHGHFVLKK-UHFFFAOYSA-N n-(3-fluoropyridin-4-yl)-5-[5-(furan-3-yl)-2-methoxypyridin-3-yl]thiophene-2-carboxamide Chemical compound COC1=NC=C(C2=COC=C2)C=C1C(S1)=CC=C1C(=O)NC1=CC=NC=C1F DTLUVEHGHFVLKK-UHFFFAOYSA-N 0.000 claims 1
- GSIKMDWORFZBHK-UHFFFAOYSA-N n-(3-methylpyridin-4-yl)-5-[2-methyl-5-(trifluoromethyl)phenyl]thiophene-2-carboxamide Chemical compound CC1=CN=CC=C1NC(=O)C1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)C)S1 GSIKMDWORFZBHK-UHFFFAOYSA-N 0.000 claims 1
- HITMRZCDQKQPRQ-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3,4-oxadiazol-2-yl)phenyl]thiophen-2-yl]-3,5-difluoropyridine-4-carboxamide Chemical compound FC1=CN=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=NN=2)Cl)S1 HITMRZCDQKQPRQ-UHFFFAOYSA-N 0.000 claims 1
- PFNAMIILXMEDTB-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3,4-oxadiazol-2-yl)phenyl]thiophen-2-yl]-3-fluoropyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=NN=2)Cl)S1 PFNAMIILXMEDTB-UHFFFAOYSA-N 0.000 claims 1
- MQXJKPNEOSDNNJ-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]thiophen-2-yl]-3,5-difluoropyridine-4-carboxamide Chemical compound FC1=CN=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)S1 MQXJKPNEOSDNNJ-UHFFFAOYSA-N 0.000 claims 1
- PJCNFAKFDYEKIT-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]thiophen-2-yl]-3-fluoropyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)S1 PJCNFAKFDYEKIT-UHFFFAOYSA-N 0.000 claims 1
- ZVFJVCLFOLOFQU-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]thiophen-2-yl]-3-methylpyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)S1 ZVFJVCLFOLOFQU-UHFFFAOYSA-N 0.000 claims 1
- XKCSACBZNUJQIR-UHFFFAOYSA-N n-[[5-[2-chloro-5-(trifluoromethyl)phenyl]thiophen-2-yl]methyl]-2,6-difluoroaniline Chemical compound FC1=CC=CC(F)=C1NCC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)S1 XKCSACBZNUJQIR-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ULLOLCOGLOVEJW-UHFFFAOYSA-N propyl 3-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]-4-methylbenzoate Chemical compound CCCOC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CC=CC=2F)F)=C1 ULLOLCOGLOVEJW-UHFFFAOYSA-N 0.000 claims 1
- RHHIWQKBUOFCJH-UHFFFAOYSA-N propyl 3-[5-[(3,5-difluoropyridin-4-yl)carbamoyl]thiophen-2-yl]-4-methylbenzoate Chemical compound CCCOC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2F)F)=C1 RHHIWQKBUOFCJH-UHFFFAOYSA-N 0.000 claims 1
- XZIQCGKMEVVBFQ-UHFFFAOYSA-N propyl 4-[5-[(2,6-difluorophenyl)carbamoyl]thiophen-2-yl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OCCC)=CC=C1C1=CC=C(C(=O)NC=2C(=CC=CC=2F)F)S1 XZIQCGKMEVVBFQ-UHFFFAOYSA-N 0.000 claims 1
- SCXRCDWGJSDYGZ-UHFFFAOYSA-N propyl 4-chloro-3-[5-[(3,5-difluoropyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound CCCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2F)F)=C1 SCXRCDWGJSDYGZ-UHFFFAOYSA-N 0.000 claims 1
- JVMLBUUWXUFVHQ-UHFFFAOYSA-N propyl 4-chloro-3-[5-[(3-methylpyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound CCCOC(=O)C1=CC=C(Cl)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2)C)=C1 JVMLBUUWXUFVHQ-UHFFFAOYSA-N 0.000 claims 1
- YTEPUVOPMKUXAZ-UHFFFAOYSA-N propyl 4-methyl-3-[5-[(3-methylpyridin-4-yl)carbamoyl]thiophen-2-yl]benzoate Chemical compound CCCOC(=O)C1=CC=C(C)C(C=2SC(=CC=2)C(=O)NC=2C(=CN=CC=2)C)=C1 YTEPUVOPMKUXAZ-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64677205P | 2005-01-25 | 2005-01-25 | |
| US60/646,772 | 2005-01-25 | ||
| PCT/US2006/002872 WO2006081389A1 (en) | 2005-01-25 | 2006-01-25 | Thiophene compounds for inflammation and immune-related uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013003649A Division JP2013064019A (ja) | 2005-01-25 | 2013-01-11 | 炎症及び免疫に関連する用途に用いる化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008528519A JP2008528519A (ja) | 2008-07-31 |
| JP2008528519A5 true JP2008528519A5 (https=) | 2013-03-07 |
| JP5221147B2 JP5221147B2 (ja) | 2013-06-26 |
Family
ID=36740852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007552413A Expired - Fee Related JP5221147B2 (ja) | 2005-01-25 | 2006-01-25 | 炎症及び免疫に関連する用途に用いる化合物 |
| JP2013003649A Pending JP2013064019A (ja) | 2005-01-25 | 2013-01-11 | 炎症及び免疫に関連する用途に用いる化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013003649A Pending JP2013064019A (ja) | 2005-01-25 | 2013-01-11 | 炎症及び免疫に関連する用途に用いる化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8802721B2 (https=) |
| EP (1) | EP1846388A4 (https=) |
| JP (2) | JP5221147B2 (https=) |
| AU (1) | AU2006208043B2 (https=) |
| CA (1) | CA2595000C (https=) |
| TW (1) | TWI444187B (https=) |
| WO (1) | WO2006081389A1 (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1848435T3 (pl) | 2005-01-25 | 2016-08-31 | Synta Pharmaceuticals Corp | Związki przeciwko zapaleniom i zastosowania związane z odpornością |
| TW200806641A (en) * | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted aromatic compounds for inflammation and immune-related uses |
| US7816535B2 (en) * | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| TW200806290A (en) * | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted biaryl compounds for inflammation and immune-related uses |
| AU2007227210A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| US8263641B2 (en) * | 2007-09-10 | 2012-09-11 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US20110052643A1 (en) * | 2008-01-07 | 2011-03-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| TWI392673B (zh) | 2008-08-27 | 2013-04-11 | Calcimedica Inc | 調控細胞內鈣離子濃度之化合物 |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| AU2009300317A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8143269B2 (en) * | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| AR076373A1 (es) * | 2009-04-24 | 2011-06-08 | Glaxo Group Ltd | N-pirazolil carboxamidas como inhibidores de canales de calcio |
| EP2421834A1 (en) * | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| AU2010289353B2 (en) * | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| EP2477982A4 (en) * | 2009-09-16 | 2013-04-03 | Calcimedica Inc | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| ES2638370T3 (es) * | 2009-11-23 | 2017-10-20 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Inhibidores del complejo PP1/GADD34 para el tratamiento de una afección que requiera una actividad inmunosupresora |
| EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP6112486B2 (ja) | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| US8765797B2 (en) | 2010-06-21 | 2014-07-01 | Board Of Regents, The University Of Texas System | TG2 inhibitors and uses thereof |
| EP2609095A4 (en) | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| US9333193B2 (en) * | 2010-09-20 | 2016-05-10 | University Of Virginia Patent Foundation | Compositions and methods for treating tuberculosis |
| AU2011322068B2 (en) * | 2010-10-30 | 2015-11-05 | Lupin Limited | Oxazoline and isoxazoline derivatives as CRAC modulators |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CA2871270A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| WO2013164773A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyrazole compounds as crac modulators |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| WO2014203217A1 (en) | 2013-06-21 | 2014-12-24 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| WO2014207648A1 (en) | 2013-06-24 | 2014-12-31 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
| CN104725347A (zh) * | 2015-02-11 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一类烷氧基取代的含甲氧苯基噻吩酰胺类结构的化合物及用途 |
| CN104725346A (zh) * | 2015-02-11 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一种腈基取代的甲氧苯噻吩酰胺类双靶点抑制剂及其用途 |
| EP3778595B1 (en) | 2015-02-27 | 2021-08-25 | Calcimedica, Inc. | Pancreatitis treatment |
| DK3324977T3 (da) | 2015-07-22 | 2022-10-17 | Enanta Pharm Inc | Benzodiazepinderivater som rsv-inhibitorer |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| EP3402799B1 (en) | 2016-01-15 | 2022-05-04 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| CN106008496B (zh) * | 2016-05-31 | 2018-06-19 | 华南农业大学 | S-(5-取代-1,3,4-噻二唑)-(5-取代苯基)-2-呋喃硫代甲酸酯类化合物及其制备方法和应用 |
| US10398706B2 (en) | 2017-01-06 | 2019-09-03 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as RSV inhibitors |
| CN110809472B (zh) | 2017-02-16 | 2023-05-23 | 英安塔制药有限公司 | 用于制备苯二氮䓬衍生物的方法 |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| WO2019006291A1 (en) * | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019043642A1 (en) * | 2017-08-31 | 2019-03-07 | Ahammune Biosciences Private Limited | NOVEL THIOPHEN COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USE THEREOF |
| BR112020006334A2 (pt) | 2017-09-29 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | combinação de agentes farmacêuticos como inibidores de rsv |
| CA3080138A1 (en) | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives |
| US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| WO2019199908A1 (en) | 2018-04-11 | 2019-10-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| WO2020053834A1 (en) | 2018-09-14 | 2020-03-19 | Rhizen Pharmaceuticals Sa | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| BR112021018335A2 (pt) | 2019-03-18 | 2021-11-23 | Enanta Pharm Inc | Derivados de benzodiazepina como inibidores de rsv |
| WO2020210246A1 (en) | 2019-04-09 | 2020-10-15 | Enanta Pharmaceuticals, Inc, | Heterocyclic compounds as rsv inhibitors |
| AU2020357452B2 (en) | 2019-10-04 | 2026-01-29 | Enanta Pharmaceuticals, Inc | Antiviral heterocyclic compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| WO2021167434A1 (ko) * | 2020-02-20 | 2021-08-26 | 한양대학교 에리카산학협력단 | 금속 음극 전극, 이를 포함하는 이차 전지, 및 그 제조 방법 |
| JP2023528537A (ja) | 2020-03-20 | 2023-07-04 | カルシメディカ，インク． | 急性肺傷害及び急性呼吸窮迫症候群を処置するための方法及び組成物 |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| CA3198798A1 (en) | 2020-11-13 | 2022-05-19 | Kenneth Stauderman | Improved synthesis of crac channel inhibitors |
| US12612412B2 (en) | 2021-02-26 | 2026-04-28 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| GB202300021D0 (en) * | 2023-01-03 | 2023-02-15 | Thirtyfivebio Ltd | Compounds |
| KR20250147900A (ko) * | 2024-04-01 | 2025-10-14 | 단국대학교 천안캠퍼스 산학협력단 | 신규 티오펜 유도체 및 이의 용도 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187232A (en) | 1975-06-05 | 1980-02-05 | Lilly Industries Limited | Acylamino derivatives |
| GB1548398A (en) * | 1975-06-05 | 1979-07-11 | Lilly Industries Ltd | Acylamino pyrroles furans and thiophenes |
| DE4233198A1 (de) * | 1992-10-02 | 1994-04-07 | Bayer Ag | Substituierte Thiophencarbonsäureamide |
| GB9424379D0 (en) * | 1994-12-02 | 1995-01-18 | Agrevo Uk Ltd | Fungicides |
| JP4385414B2 (ja) | 1997-10-13 | 2009-12-16 | アステラス製薬株式会社 | アミド若しくはアミン誘導体 |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
| IL162533A0 (en) | 2001-12-19 | 2005-11-20 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20060178403A1 (en) | 2003-03-07 | 2006-08-10 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
| WO2004082677A1 (en) | 2003-03-21 | 2004-09-30 | H. Lundbeck A/S | Substituted p-diaminobenzene derivatives |
| WO2004103960A2 (en) * | 2003-05-16 | 2004-12-02 | Ambit Biosciences Corporation | Compounds and uses thereof |
| TWI376370B (en) * | 2003-07-23 | 2012-11-11 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
| ATE501138T1 (de) | 2004-01-05 | 2011-03-15 | Astrazeneca Ab | Thiophenderivate als chk-1-inhibitoren |
| KR20070057965A (ko) | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| KR20140018997A (ko) | 2005-01-07 | 2014-02-13 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| PL1848435T3 (pl) | 2005-01-25 | 2016-08-31 | Synta Pharmaceuticals Corp | Związki przeciwko zapaleniom i zastosowania związane z odpornością |
| TW200806290A (en) | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted biaryl compounds for inflammation and immune-related uses |
| US20070254926A1 (en) | 2006-01-31 | 2007-11-01 | Jun Jiang | Pyridylphenyl compounds for inflammation and immune-related uses |
| AU2007227210A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| AU2007230911A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| US20080207641A1 (en) | 2006-11-13 | 2008-08-28 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
| JP2010519206A (ja) | 2007-02-16 | 2010-06-03 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連使用のための置換縮合環化合物 |
| CA2695143A1 (en) | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Heterocycle-aryl compounds for inflammation and immune-related uses |
| CA2695148A1 (en) | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Pyridine compounds for inflammation and immune-related uses |
| WO2009017831A1 (en) | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Vinyl-aryl derivatives for inflammation and immune-related uses |
| US8324219B2 (en) | 2007-09-20 | 2012-12-04 | Synta Pharmaceuticals Corp. | Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| US20110052643A1 (en) | 2008-01-07 | 2011-03-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
-
2006
- 2006-01-25 EP EP06719650A patent/EP1846388A4/en not_active Withdrawn
- 2006-01-25 CA CA2595000A patent/CA2595000C/en not_active Expired - Fee Related
- 2006-01-25 US US11/340,292 patent/US8802721B2/en not_active Expired - Fee Related
- 2006-01-25 JP JP2007552413A patent/JP5221147B2/ja not_active Expired - Fee Related
- 2006-01-25 AU AU2006208043A patent/AU2006208043B2/en not_active Ceased
- 2006-01-25 TW TW095102770A patent/TWI444187B/zh not_active IP Right Cessation
- 2006-01-25 WO PCT/US2006/002872 patent/WO2006081389A1/en not_active Ceased
-
2013
- 2013-01-11 JP JP2013003649A patent/JP2013064019A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528519A5 (https=) | ||
| JP2008528520A5 (https=) | ||
| RU2006131132A (ru) | 1,3,5,-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью | |
| JP2022515197A5 (https=) | ||
| AU2016228207B2 (en) | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | |
| JP2010077141A5 (https=) | ||
| JP2013508279A5 (https=) | ||
| JP2009542699A5 (https=) | ||
| JP2012504133A5 (https=) | ||
| JP2007508360A5 (https=) | ||
| JP2020500866A5 (https=) | ||
| JP2013529210A5 (https=) | ||
| JP2009535307A5 (https=) | ||
| JP2010090138A5 (https=) | ||
| JP2015504081A5 (https=) | ||
| JP2011510055A5 (https=) | ||
| JP2007520452A5 (https=) | ||
| JP2006501298A5 (https=) | ||
| RU2006130000A (ru) | Органические соединения | |
| JP2021504384A5 (https=) | ||
| RU2014132564A (ru) | Хитозан, ковалентно связанный с низкомолекулярным антагонистом интегрина, для нацеленной доставки | |
| JP2010506919A5 (https=) | ||
| JP2020111571A5 (https=) | ||
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| JP2008521934A5 (https=) |